Abstract

Tamoxifen citrate, the non-steroidal anti-estrogen and the first selective estrogen receptor modulator is the treatment of choice for patients with all stages of estrogen receptor positive breast cancer. Although Cytochrome P-450s (CYP) are well known to be responsible for much of its metabolism, fragmentary studies have been carried out to analyze the activity of xanthine oxidase, a non-CYP drug metabolizing enzyme, in tamoxifen metabolism. So, the present investigation is aimed to ascertain the effect of tablet and nano-formulation of tamoxifen on xanthine oxidase expression during 3-methylcholanthrene-induced carcinogenesis. It is found that oral administration of tamoxifen in both the formulations significantly (p < 0.01) decreases the xanthine oxidase activity in liver tissue of female mice. We speculate our results to be beneficial for the better understanding of drug metabolism and intensity, which in turn will pave the way for new and efficient nano-formulations of drug coming into therapeutic use.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.